Quest Diagnostics Receives “Neutral” Rating from Citigroup Inc. (DGX)
Quest Diagnostics (NYSE:DGX)‘s stock had its “neutral” rating restated by stock analysts at Citigroup Inc. in a report issued on Friday. They currently have a $65.00 target price on the stock, up from their previous target price of $60.00. Citigroup Inc.’s target price would suggest a potential upside of 4.60% from the company’s current price.
DGX has been the subject of a number of other recent research reports. Analysts at Maxim Group raised their price target on shares of Quest Diagnostics from $68.00 to $74.00 in a research note on Friday. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Quest Diagnostics from $55.00 to $58.00 in a research note on Friday. They now have a “hold” rating on the stock. Finally, analysts at Mizuho reiterated a “neutral” rating on shares of Quest Diagnostics in a research note on Thursday. One analyst has rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $61.31.
Quest Diagnostics (NYSE:DGX) traded up 1.16% on Friday, hitting $62.14. The stock had a trading volume of 1,468,828 shares. Quest Diagnostics has a 52-week low of $50.46 and a 52-week high of $64.10. The stock’s 50-day moving average is $59.85 and its 200-day moving average is $56.74. The company has a market cap of $8.978 billion and a price-to-earnings ratio of 11.26.
Quest Diagnostics (NYSE:DGX) last released its earnings data on Thursday, July 24th. The company reported $1.08 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.06 by $0.02. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter in the prior year, the company posted $1.06 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Analysts expect that Quest Diagnostics will post $4.03 EPS for the current fiscal year.
Quest Diagnostics Incorporated (NYSE:DGX) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.